Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, Sirpa Leppa, Maria Gomes da Silva, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, Hans Hagberg, P. J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. ChristensenMilada Jankovska, Par L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, Mats A. Merup, Thomas Noesslinger, Eric Van den Neste, Josee M. Zijlstra, Georg Hopfinger, V. I. T. Prochazka, Esa Jantunen, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M. A. Delabie, Laurence de Leval, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundstrom, Lorenz Truemper, Gerald Wulf, Lauren Chong, Alyssa Bouska, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, Markus Loeffler, Knut Liestol, Christian Steidl, Randy D. Gascoyne, David W. Scott, Bettina Altmann, Javeed Iqbal, Wing C. Chan, Helle Toldbod

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Number of pages6
JournalBlood
Volume132
Issue numberSuppl.1
Publication statusPublished - 29-Nov-2018
Event60th Annual Meeting of the American-Society-of-Hematology (ASH) - San Diego, California, United States
Duration: 1-Dec-20184-Dec-2018

Cite this